Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 20;37(12):1100-1103.
doi: 10.1515/jpem-2024-0194. Print 2024 Dec 17.

Mineralocorticoid receptor antagonist monotherapy in pediatric non-classical 11β-hydroxylase deficiency

Elaine C Kennedy  1   2 , Maria Stack  3 , Eirin Carolan  4 , Maeve Durkan  5 , Caroline M Joyce  1   6 , Colin P Hawkes  1   2   7
Affiliations
Case Reports

Mineralocorticoid receptor antagonist monotherapy in pediatric non-classical 11β-hydroxylase deficiency

Elaine C Kennedy et al. J Pediatr Endocrinol Metab. .

Abstract

Objectives: Congenital adrenal hyperplasia (CAH) is an uncommon genetic disorder which affects cortisol production in the adrenal glands. It is usually treated with glucocorticoids. We present a case of non-classical CAH caused by the partial deficiency of 11 beta-hydroxylase (11βOH) which was treated with aldosterone antagonist (eplerenone) monotherapy.

Case presentation: An adolescent male was diagnosed with 11 beta-hydroxylase deficiency (11βOHD) at 13 years of age when he presented with hypertension, fatigue and headaches. He was initially treated with glucocorticoids, but requested an alternative therapy. Eplerenone was commenced at 25 mg with subsequent dose increases to 100 mg daily. His hypertension was controlled on this regimen, achieving a 24 h average blood pressure of 124/81 mmHg.

Conclusions: CAH caused by 11βOHD is a known cause of hypertension. It is usually managed with glucocorticoids, and antihypertensives are added if blood pressure remains uncontrolled. In this case, glucocorticoid therapy was not tolerated and treatment with aldosterone antagonist monotherapy was effective in controlling his hypertension.

Keywords: 11 beta-hydroxylase deficiency; 11-deoxycortisol; congenital adrenal hyperplasia; eplerenone.

PubMed Disclaimer

References

    1. Khattab, A, Haider, S, Kumar, A, Dhawan, S, Alam, D, Romero, R, et al.. Clinical, genetic, and structural basis of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Proc Natl Acad Sci USA 2017;114:E1933–e40. https://doi.org/10.1073/pnas.1621082114 . - DOI
    1. Bulsari, K, Falhammar, H. Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency. Endocrine 2017;55:19–36. https://doi.org/10.1007/s12020-016-1189-x . - DOI
    1. Mooij, CF, Parajes, S, Rose, IT, Taylor, AE, Bayraktaroglu, T, Wass, JA, et al.. Characterization of the molecular genetic pathology in patients with 11β-hydroxylase deficiency. Clin Endocrinol (Oxf) 2015;83:629–35. https://doi.org/10.1111/cen.12834 . - DOI
    1. Hinz, L, Pacaud, D, Kline, G. Congenital adrenal hyperplasia causing hypertension: an illustrative review. J Hum Hypertens 2018;32:150–7. https://doi.org/10.1038/s41371-017-0002-5 . - DOI
    1. White, PC, Curnow, KM, Pascoe, L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocr Rev 1994;15:421–38. https://doi.org/10.1210/edrv-15-4-421 . - DOI

Publication types

MeSH terms

Substances

Supplementary concepts